title: Management of retinal vascular diseases: a patient-centric approach.
abstract: Retinal vascular diseases are a leading cause of blindness in the Western world. Advancement in the clinical management of these diseases has been fast-paced, with new treatments becoming available as well as license extensions of existing treatments. Vascular endothelial growth factor (VEGF) has been implicated in certain retinal vascular diseases, including wet age-related macular degeneration (AMD), diabetic macular oedema (DMO), and retinal vein occlusion (RVO). Treatment of wet AMD and visual impairment due to either DMO or macular oedema secondary to RVO with an anti-VEGF on an as needed basis, rather than a fixed schedule, allows an individualised treatment approach; providing treatment when patients are most likely to benefit from it, while minimising the number of unnecessary intravitreal injections. Thus, an individualised treatment regimen reduces the chances of over-treatment and under-treatment, optimising both the risk/benefit profile of the treatment and the efficient use of NHS resource. Streamlining of treatment for patients with wet AMD and visual impairment due to either DMO or macular oedema secondary to RVO, by using one treatment with similar posology across all three diseases, may help to minimise burden of clinic capacity and complexity and hence optimise patient outcomes. Informed treatment decisions and efficient clinic throughput are important for optimal patient outcomes in the fast-changing field of retinal vascular diseases.
authors.affiliation: Eye Department, Royal Hallamshire Hospital, Sheffield, UK. christopher.brand@sth.nhs.uk
authors.forename: C S
authors.initials: CS
authors.lastname: Brand
mesh_terms: D000305:Adrenal Cortex Hormones / Q000627:therapeutic use; D020533:Angiogenesis Inhibitors / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D003930:Diabetic Retinopathy / Q000150:complications; D006801:Humans; D008268:Macular Degeneration / Q000188:drug therapy; D008269:Macular Edema / Q000188:drug therapy / Q000209:etiology; D018802:Patient-Centered Care; D012164:Retinal Diseases / Q000175:diagnosis / Q000188:drug therapy*; D012170:Retinal Vein Occlusion / Q000150:complications / Q000188:drug therapy; D042442:Vascular Endothelial Growth Factors / Q000037:antagonists & inhibitors*
chemical_list: D000305:Adrenal Cortex Hormones; D020533:Angiogenesis Inhibitors; D042442:Vascular Endothelial Growth Factors